Your browser doesn't support javascript.
The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19.
Callender, Lauren A; Curran, Michelle; Bates, Stephanie M; Mairesse, Maelle; Weigandt, Julia; Betts, Catherine J.
  • Callender LA; Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Curran M; Department of Surgery, University of Cambridge, NIHR Cambridge Biomedical, Cambridge, United Kingdom.
  • Bates SM; Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Mairesse M; Department of Surgery, University of Cambridge, NIHR Cambridge Biomedical, Cambridge, United Kingdom.
  • Weigandt J; Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Betts CJ; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom.
Front Immunol ; 11: 1991, 2020.
Article in English | MEDLINE | ID: covidwho-742729
ABSTRACT
Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Comorbidity / Coronavirus Infections Type of study: Etiology study / Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Front Immunol Year: 2020 Document Type: Article Affiliation country: Fimmu.2020.01991

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Comorbidity / Coronavirus Infections Type of study: Etiology study / Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Front Immunol Year: 2020 Document Type: Article Affiliation country: Fimmu.2020.01991